Amin Haiderali

907 total citations
52 papers, 561 citations indexed

About

Amin Haiderali is a scholar working on Oncology, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Amin Haiderali has authored 52 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 27 papers in Cancer Research and 19 papers in Economics and Econometrics. Recurrent topics in Amin Haiderali's work include Breast Cancer Treatment Studies (25 papers), Economic and Financial Impacts of Cancer (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Amin Haiderali is often cited by papers focused on Breast Cancer Treatment Studies (25 papers), Economic and Financial Impacts of Cancer (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Amin Haiderali collaborates with scholars based in United States, United Kingdom and Germany. Amin Haiderali's co-authors include Min Huang, Margaret Good, April Teitelbaum, Laura Menditto, Peter A. Fasching, Javier Cortés, Joyce O’Shaughnessy, Keith Tolley, Lee S. Schwartzberg and Peter Schmid and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Amin Haiderali

51 papers receiving 550 citations

Peers

Countries citing papers authored by Amin Haiderali

Since Specialization

Citations

This map shows the geographic impact of Amin Haiderali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amin Haiderali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amin Haiderali more than expected).

Fields of papers citing papers by Amin Haiderali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amin Haiderali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amin Haiderali. The network helps show where Amin Haiderali may publish in the future.

Co-authorship network of co-authors of Amin Haiderali

This figure shows the co-authorship network connecting the top 25 collaborators of Amin Haiderali. A scholar is included among the top collaborators of Amin Haiderali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amin Haiderali. Amin Haiderali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009 2024 ·ESMO Open ·Antonio Llombart‐Cussac, (unknown), Mark E. Robson, (unknown), (unknown), Eduardo Yañez Ruiz, (unknown), J.M. Walshe, Y-H Im, Svitlana Kulyk, Alexander S. Dudnichenko, (unknown), Shigehira Saji, (unknown), (unknown), Amin Haiderali, (unknown), Allison Martin Nguyen, (unknown), David W. Cescon	3
2	A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers 2024 ·Oncology and Therapy ·Matthew Monberg, (unknown), Vassiliki Karantza, Konstantinos Tryfonidis, Sarper Toker, Jaime Mejia, Robert Orlowski, Amin Haiderali, Vimalanand S. Prabhu, Gursel Aktan	1
3	Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States 2023 ·Advances in Therapy ·Min Huang, Peter A. Fasching, Amin Haiderali, (unknown), (unknown), Wilbur Pan, Zheng‐Yi Zhou, (unknown), (unknown), Celine Le Bailly De Tilleghem, (unknown), Joyce O’Shaughnessy	14
4	Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 2023 ·JNCI Journal of the National Cancer Institute ·David W. Cescon, Peter Schmid, Hope S. Rugo, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, José Manuel Pérez-García, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Amin Haiderali, Xuan Zhou, Zifang Guo, Allison Martin Nguyen, Javier Cortés	7
5	Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis 2023 ·BMC Cancer ·Javier Cortés, Amin Haiderali, Min Huang, Wilbur Pan, Peter Schmid, Katherine G. Akers, Julie E. Park, Andrew M. Frederickson, Peter A. Fasching, Joyce O’Shaughnessy	13
6	164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355 2022 ·Annals of Oncology ·David W. Cescon, (unknown), H. S. Rugo, S-A. Im, Mastura Md Yusof, (unknown), Oleg Lipatov, Carlos H. Barrios, José Manuel Pérez García, Hiromitsu Iwata, Norikazu Masuda, (unknown), Erhan Gökmen, Sherene Loi, Amin Haiderali, Xiaoyan Zhou, (unknown), Allison Martin Nguyen, (unknown)	2
7	Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review 2022 ·PharmacoEconomics ·Min Huang, Amin Haiderali, (unknown), Andrew M. Frederickson, Javier Cortés, Peter A. Fasching, Joyce O’Shaughnessy	29
8	PCN248 Productivity Costs Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer 2021 ·Value in Health ·(unknown), Amin Haiderali, (unknown), Kim M. Hirshfield, (unknown), (unknown), (unknown), (unknown)	1
9	The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States 2021 ·Advances in Therapy ·(unknown), Yan Song, (unknown), Min Huang, Amin Haiderali, Richard Berman, (unknown), James Signorovitch, Kim M. Hirshfield	13
10	Real-World Treatment Patterns and Effectiveness Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer 2021 ·Future Oncology ·Amin Haiderali, (unknown), (unknown), Min Huang, (unknown), (unknown), Lee S. Schwartzberg	8
11	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis 2020 ·Cancer Research ·Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortés, Scott D. Ramsey, Andrew Briggs, (unknown), Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, (unknown), John S. Cook, Michael Untch, Peter Schmid, Peter A. Fasching	89
12	141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer 2020 ·Annals of Oncology ·Peter Schmid, Amin Haiderali, Jaime Mejia, (unknown), Xuan Zhou, (unknown), Javier Cortés, Eric P. Winer	6
13	PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS 2019 ·Value in Health ·Andrew M. Frederickson, Amin Haiderali, (unknown), Aeson Chang, Min Huang	1
14	PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS 2019 ·Value in Health ·Andrew M. Frederickson, Amin Haiderali, (unknown), Aeson Chang, Min Huang	1
15	Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy 2019 ·Annals of Oncology ·Min Huang, (unknown), Scott D. Ramsey, Andrew Briggs, Jing Zhao, Amin Haiderali, Vassiliki Karantza, Jipan Xie, (unknown), Peter A. Fasching	5
16	Cost-Effectiveness Of Ofatumumab Plus Chlorambucil In First-Line Chronic Lymphocytic Leukemia In The United Kingdom 2015 ·Value in Health ·(unknown), Emma Hawe, (unknown), Sorrel Wolowacz, Amin Haiderali	1
17	Use Of External Data To Guide Long-Term Survival Extrapolations Of Trial Data For Chronic Lymphocytic Leukemia 2014 ·Value in Health ·Emma Hawe, (unknown), Sorrel Wolowacz, Amin Haiderali	2
18	PCN120 The Natural History of Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients Who Fail Alemtuzumab or Have Bulky Lymphadenopathy – A European Perspective 2011 ·Value in Health ·E De Cock, Amin Haiderali, Radoslaw Wasiak, Y. Lis, Vincent Lévy	1
19	Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population 2010 ·Supportive Care in Cancer ·Amin Haiderali, Laura Menditto, Margaret Good, April Teitelbaum, (unknown)	95
20	Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy 2009 ·Supportive Care in Cancer ·Cesare Gridelli, Amin Haiderali, Mark W. Russo, (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact